Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

Hepatitis and HIV news

Show

From To
WHO recommends global use of newest hepatitis C drugs, urges price reductions

The World Health Organization has issued global treatment guidelines for hepatitis C, strongly recommending the use of the new direct-acting antivirals sofosbuvir (Sovaldi) with ribavirin for genotypes 1,

Published
09 April 2014
By
Keith Alcorn
WHO joins clamour to make new hepatitis C pills affordable

The World Health Organisation wants a "concerted effort" to drive down the cost of new hepatitis C drugs that offer a cure for the liver-destroying virus but are unaffordable for most infected people worldwide.

Published
09 April 2014
From
Reuters
WHO issues its first hepatitis C treatment guidelines

WHO has issued its first guidance for the treatment of hepatitis C, a chronic infection that affects an estimated 130 million to 150 million people and results in 350 000 to 500 000 deaths a year.

Published
09 April 2014
From
World Health Organization
WHO Hepatitis Treatment Guidelines: UNITAID Urges Efforts to Improve Diagnosis as Key to Increase Access to Medicines

Developing simpler, quicker and more affordable viral load technologies is the key to vastly improved management of the hepatitis C virus.

Published
09 April 2014
From
UNITAID
Gilead Sciences: How serious is the pricing problem?

There really isn’t much precedent at all for branded companies competing on price in a MAJOR (~double digit) way. Plenty of companies play around with rebates and discounts, but it’s rare that the net price difference between major brands is more than a few percentage points.

Published
09 April 2014
From
Barron's
Gilead aims to license hepatitis C drug to 3-4 Indian firms

Gilead Sciences aims to license its new hepatitis C drug Sovaldi to three or four Indian generic manufacturers to allow sales of the medicine at lower prices in some 60 developing nations.

Published
09 April 2014
From
Reuters
Express Scripts Raises Pressure on Gilead for Drug Price

Express Scripts Holding Co. (ESRX), a pharmacy benefit manager that handles more than 1 billion prescriptions annually in the U.S., is ratcheting up its effort to force Gilead Sciences Inc. (GILD) to cut the $84,000 price of its new hepatitis C pill Sovaldi.

Published
08 April 2014
From
Bloomberg
First European Conference on Hepatitis C and Drug Use, Berlin, 23-24 October 2014

One of the highlights during the conference will be the presentation of the 'Berlin Declaration', a pressing call to national and European policy makers, to ensure better access and quality of HCV treatment for the most marginalised groups and individuals.

Published
07 April 2014
From
EATG
Costs to public of $84,000 hep C drug ‘outrageous' - Kaiser Permanente

Kaiser Permanente, the biggest U.S. health maintenance organization, said it is using Gilead Sciences' new hepatitis C drug, Sovaldi, even though its $84,000 treatment price is "outrageous."

Published
03 April 2014
From
Reuters
Push Comes To Shove: Gilead's $1,000 Pill Could Hurt Insurer Earnings

Gilead Sciences’ $1,000-a-day hepatitis C drug, Sovaldi, could hurt earnings per share by as much as 10%, according to an analysis conducted by Leerink, the investment bank.

Published
31 March 2014
From
Forbes

Filter by country